Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
-
- Shona Hendry
- Pathology
-
- Roberto Salgado
- Department of Pathology and TCRU, GZA
-
- Thomas Gevaert
- Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven
-
- Prudence A. Russell
- Pathology
-
- Tom John
- Department of Medical Oncology, Austin Health
-
- Bibhusal Thapa
- Medicine, University of Melbourne
-
- Michael Christie
- Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville
-
- Koen van de Vijver
- Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands
-
- M.V. Estrada
- Department of Pathology, School of Medicine, University of California, San Diego
-
- Paula I. Gonzalez-Ericsson
- Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University
-
- Melinda Sanders
- Pathology, Microbiology and Immunology
-
- Benjamin Solomon
- Medical Oncology, Peter MacCallum Cancer Centre, Melbourne
-
- Cinzia Solinas
- Molecular Immunology Unit
-
- Gert G.G.M. Van den Eynden
- Department of Pathology, GZA Ziekenhuizen, Antwerp
-
- Yves Allory
- Université Paris-Est
-
- Matthias Preusser
- Department of Medicine, Clinical Division of Oncology
-
- Johannes Hainfellner
- Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna
-
- Giancarlo Pruneri
- European Institute of Oncology
-
- Andrea Vingiani
- European Institute of Oncology
-
- Sandra Demaria
- Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY
-
- Fraser Symmans
- Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX
-
- Paolo Nuciforo
- Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona
-
- Laura Comerma
- Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona
-
- E.A. Thompson
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
-
- Sunil Lakhani
- Centre for Clinical Research and School of Medicine, The University of Queensland
-
- Seong-Rim Kim
- National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA
-
- Stuart Schnitt
- Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center
-
- Cecile Colpaert
- Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk
-
- Christos Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
-
- Stefan J. Scherer
- Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover
-
- Michail Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles
-
- Sunil Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN
-
- Robert H. Pierce
- Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA
-
- Giuseppe Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan
-
- Nicolas Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
-
- Frederique Penault-Llorca
- Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre
-
- Tomohagu Sugie
- Department of Surgery, Kansai Medical School, Hirakata, Japan
-
- Susan Fineberg
- Montefiore Medical Center
-
- Soonmyung Paik
- Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea
-
- Ashok Srinivasan
- National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA
-
- Andrea Richardson
- Department of Pathology, Brigham and Women’s Hospital
-
- Yihong Wang
- Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center
-
- Ewa Chmielik
- Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center
-
- Jane Brock
- Department of Pathology, Brigham and Women’s Hospital
-
- Douglas B. Johnson
- Department of Medicine, Vanderbilt University Medical Centre
-
- Justin Balko
- Department of Medicine, Vanderbilt University Medical Centre
-
- Stephan Wienert
- Institute of Pathology, Charité Universitätsmedizin Berlin
-
- Veerle Bossuyt
- Department of Pathology, Yale University School of Medicine, New Haven
-
- Stefan Michiels
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay
-
- Nils Ternes
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay
-
- Nicole Burchardi
- German Breast Group GmbH, Neu-Isenburg, Germany
-
- Stephen J. Luen
- Medical Oncology, Peter MacCallum Cancer Centre, Melbourne
-
- Peter Savas
- Medical Oncology, Peter MacCallum Cancer Centre, Melbourne
-
- Frederick Klauschen
- Institute of Pathology, Charité Universitätsmedizin Berlin
-
- Peter H. Watson
- Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
-
- Brad H. Nelson
- Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
-
- Carmen Criscitiello
- European Institute of Oncology
-
- Sandra O’Toole
- The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst
-
- Denis Larsimont
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
-
- Roland de Wind
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
-
- Giuseppe Curigliano
- European Institute of Oncology
-
- Fabrice André
- INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif
-
- Magali Lacroix-Triki
- INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif
-
- Mark van de Vijver
- Department of Surgical Oncology, Netherlands Cancer Institute
-
- Federico Rojo
- Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain
-
- Giuseppe Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
-
- Shahinaz Bedri
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar
-
- Joseph Sparano
- Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine
-
- David Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
-
- Torsten Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC
-
- Zuzana Kos
- Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada
-
- Stephen Hewitt
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda
-
- Baljit Singh
- Department of Pathology, New York University Langone Medical Centre
-
- Gelareh Farshid
- Directorate of Surgical Pathology, SA Pathology
-
- Sibylle Loibl
- German Breast Group GmbH, Neu-Isenburg, Germany
-
- Kimberly H. Allison
- Pathology Department, Stanford University Medical Centre, Stanford
-
- Nadine Tung
- Division of Hematology-Oncology, Beth Israel Deaconess Medical Center
-
- Sylvia Adams
- New York University Medical School
-
- Karen Willard-Gallo
- Molecular Immunology Unit
-
- Hugo M. Horlings
- Department of Pathology
-
- Leena Gandhi
- Dana-Farber Cancer Institute, Boston, MA
-
- Andre Moreira
- Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University
-
- Fred Hirsch
- Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO
-
- Maria V. Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova
-
- Maria Urbanowicz
- European Organisation for Research and Treatment of Cancer (EORTC) Headquarters
-
- Iva Brcic
- Institute of Pathology, Medical University of Graz, Austria
-
- Konstanty Korski
- Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg
-
- Fabien Gaire
- Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg
-
- Hartmut Koeppen
- Research Pathology, Genentech Inc., South San Francisco, CA
-
- Amy Lo
- Department of Pathology, Stanford University, Palo Alto
-
- Jennifer Giltnane
- Research Pathology, Genentech Inc., South San Francisco, CA
-
- Marlon C. Rebelatto
- Translational Sciences, MedImmune, Gaithersberg, MD
-
- Keith E. Steele
- Translational Sciences, MedImmune, Gaithersberg, MD
-
- Jiping Zha
- Translational Sciences, MedImmune, Gaithersberg, MD
-
- Kenneth Emancipator
- Translational Medicine, Merck & Co. Inc., Kenilworth, NJ
-
- Jonathan W. Juco
- Translational Medicine, Merck & Co. Inc., Kenilworth, NJ
-
- Carsten Denkert
- Institute of Pathology, Charité Universitätsmedizin Berlin
-
- Jorge Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
-
- Sherene Loi
- Medical Oncology, Peter MacCallum Cancer Centre, Melbourne
-
- Stephen B. Fox
- Pathology
説明
<jats:p>Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.</jats:p>
収録刊行物
-
- Advances in Anatomic Pathology
-
Advances in Anatomic Pathology 24 (5), 235-251, 2017-09
Ovid Technologies (Wolters Kluwer Health)